NeuBase Therapeutics, Inc.
NBSE · NASDAQ
9/30/2022 | 9/30/2021 | 9/30/2020 | 9/30/2019 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $1,263 | $576 | $280 | $128 |
| Gross Profit | -$1,263 | -$576 | -$280 | -$128 |
| % Margin | – | – | – | – |
| R&D Expenses | $21,449 | $14,363 | $6,946 | $17,241 |
| G&A Expenses | $11,870 | $12,202 | $10,123 | $9,096 |
| SG&A Expenses | $11,870 | $12,202 | $10,123 | $9,096 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | -$167 | $450 | $412 | $0 |
| Operating Expenses | $33,318 | $26,565 | $17,069 | $26,336 |
| Operating Income | -$33,318 | -$26,565 | -$17,069 | -$26,336 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | -$458 | $1,156 | -$315 | -$622 |
| Pre-Tax Income | -$33,776 | -$25,409 | -$17,385 | -$26,958 |
| Tax Expense | $458 | $258 | -$123 | $129 |
| Net Income | -$34,235 | -$25,667 | -$17,261 | -$27,087 |
| % Margin | – | – | – | – |
| EPS | -21.08 | -18.8 | -17.6 | -65.49 |
| % Growth | -12.1% | -6.8% | 73.1% | – |
| EPS Diluted | -21.08 | -18.8 | -17.6 | -65.49 |
| Weighted Avg Shares Out | 1,624 | 1,365 | 981 | 414 |
| Weighted Avg Shares Out Dil | 1,624 | 1,365 | 981 | 414 |
| Supplemental Information | – | – | – | – |
| Interest Income | $149 | $13 | $0 | $0 |
| Interest Expense | $24 | $32 | $8 | $129 |
| Depreciation & Amortization | $828 | $641 | $150 | $128 |
| EBITDA | -$32,924 | -$25,924 | -$17,227 | -$26,701 |
| % Margin | – | – | – | – |